Complete dosing information for IMLUNESTRANT
Medical guidance required: Dosing information here is for educational purposes. Your healthcare provider will determine the appropriate dose based on your specific condition, kidney function, other medications, and medical history. Never adjust your dose without consulting your doctor or pharmacist.
2 DOSAGE AND ADMINISTRATION Select patients for treatment based on the presence of ESR1 mutations. ( 2.1 ) The recommended dosage is 400 mg orally once daily, on an empty stomach. ( 2.2 ) Reduce the dose in patients with moderate or severe hepatic impairment ( 2.4 , 8.6 ) Dosage modifications may be required. ( 2.3 , 2.4 , 2.5 ) 2.1 Patient Selection Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with INLURIYO based on the presence of ESR1 mutation(s) in a plasma specimen using an FDA-approved test [see Indications and Usage ( 1 ) and Clinical Studies (14.1)] . Information on FDA-approved tests for the detection of ESR1 mutations in breast cancer is available at: https://www.fda.gov/CompanionDiagnostics . 2.2 Recommended Dosage and Administration The recommended dosage of INLURIYO is 400 mg orally once daily until disease progression or unacceptable toxicity. Take on an empty stomach at least 2 hours before food, or 1 hour after food [s